Document:

EXHIBIT 10.1

 

SUBSCRIPTION
AGREEMENT

 

Applied
DNA Sciences, Inc.

50 Health Sciences Drive

Stony Brook, New York 11790

 

Gentlemen and Ladies:

 

The undersigned (the
“Subscriber”) hereby subscribes for ______________ shares (the “Shares”) of common stock,
par value $0.001 per share (“Common Stock”), of Applied DNA Sciences, Inc., a Delaware corporation (the “Company”),
at a cash purchase price per share of $0.27 (the “Purchase Price”), which represents the higher of (i) the lower
of (x) the closing price per share of Common Stock (as reflected on Nasdaq.com) on the trading day immediately preceding the date
hereof or (y) the average closing price per share of Common Stock (as reflected on Nasdaq.com) for the five trading days immediately
preceding the date hereof and (ii) the consolidated closing bid price per share of Common Stock on the trading day immediately
preceding the date hereof, for an aggregate purchase price of $0.27. 
The Subscriber is one of several persons subscribing for Common Stock on or about the date hereof, but each such person may elect
to have a different Payment Date (as defined below).

 

1.                          Subscription.
Subject to the terms and conditions hereof, the Subscriber agrees to pay $____________ by check or wire transfer of immediately
available funds as consideration (the “Payment”) for the Subscriber’s Shares. Subscriber agrees that the
Payment shall be made within 5 days of the date hereof (the date of such payment, the “Payment Date”). Subscriber
agrees that regardless of the date of the Payment Date, the Purchase Price will not change. The Subscriber acknowledges and agrees
that this subscription is irrevocable by the Subscriber but is subject to acceptance by the Company. The Subscriber agrees that
it will have no rights as a holder of Common Stock until the Payment is received by the Company.

 

2.                          Subscription
Compliance. The Subscriber agrees that this subscription is subject to the following terms and conditions:

 

The Company shall have the right, in its
sole discretion, to: (i) accept or reject this subscription; (ii) determine whether this Subscription Agreement has been properly
completed by the Subscriber and (iii) determine whether the Subscriber has met all of the Company’s requirements for investment
in the Shares. If the Company deems this subscription to be defective, deficient or otherwise non-compliant with the terms of this
offering, the Subscriber’s funds will be returned promptly to the Subscriber without interest or deduction.

 

3.                          Receipt
of Information.

 

a.                          The
Subscriber and Subscriber’s purchaser representative, if any, have reviewed a copy of the Company’s most recent Annual
Report on Form 10-K, as amended, Quarterly Reports on Form 10-Q and current reports on Form 8-K. The Subscriber, either alone or
together with Subscriber’s purchaser representative, if any, have such knowledge and experience in financial and business
matters as to be able to evaluate the merits and risks of an investment in the Company. Since August 13, 2019, the date of filing
of the Company’s most recent Quarterly Report on Form 10-Q, there has been no material adverse change in the business, properties,
or results of operations of the Company.

 

     

     

    

 

b.                          The
Subscriber and Subscriber’s representative, if any, have had the opportunity to ask questions of and receive answers from
the Company concerning the terms and conditions of the offering of the Shares by the Company and to obtain any additional information
Subscriber has requested which is necessary to verify the accuracy of the information furnished to the Subscriber concerning the
Company and such offering.

 

4.                          Representations
of Subscriber. In connection with the purchase of the Shares, the Subscriber hereby represents and warrants to the Company
as follows:

 

a.                          The
Subscriber is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under the Securities Act
of 1933, as amended (the “Act”).

 

b.                          The
Shares are being purchased for the Subscriber’s own account without the participation of any other person, with the intent
of holding the Shares for investment and without the intent of participating, directly or indirectly, in a distribution of the
Shares and not with a view to, or for a resale in connection with, any distribution of the Shares or any portion thereof, nor is
the undersigned aware of the existence of any distribution of the Company’s securities. Furthermore, the undersigned has
no present intention of dividing such Shares with others or reselling or otherwise disposing of any portion of such Shares, either
currently or after the passage of a fixed or predeterminable period of time, or upon the occurrence or nonoccurrence of any predetermined
event or circumstance.

 

c.                          The
Subscriber has no need for liquidity with respect to his purchase of the Shares and is able to bear the economic risk of an investment
in the Shares for an indefinite period of time and is further able to afford a complete loss of such investment.

 

d.                          The
Subscriber represents that his financial commitment to all investments (including his investment in the Company) is reasonable
relative to his net worth and liquid net worth.

 

e.                          The
Subscriber recognizes that the Shares will be sold to the Subscriber without registration under any United States federal or other
law relating to the registration of securities for sale.

 

f.                          The
Subscriber is aware that any resale of the Shares cannot be made except in accordance with the registration requirements of the
Act or an exemption therefrom.

 

g.                          The
Subscriber represents and warrants that all offers and sales of the Shares shall be made pursuant to an exemption from registration
under the Act or pursuant to registration under the Act, and the Subscriber will not engage in any hedging or short selling transactions
with regard to the Shares.

 

h.                          The
Subscriber is not acquiring the Shares based upon any representation, oral or written, by any person with respect to the future
value of, or income from, the Shares but rather upon an independent examination and judgment as to the prospects of the Company.

 

    2

     

    

 

i.                          The
Subscriber understands that the Company has had a limited operating history, and as a result, its operations have produced limited
recurring revenues from its services and products; it has incurred expenses and has sustained losses. Consequently, its operations
are subject to all the risks inherent in the establishment of a biotechnology company. The Subscriber appreciates and understands
the risks involved with investing in a Company with a limited operating history and has read and understands the risk factors and
other information set forth in the Company’s Annual Report on Form 10-K, filed on December 18, 2018 and as amended on January
28, 2019 and April 4, 2019, and the Quarterly Reports on Form 10-Q for the quarterly periods ended December 31, 2018, March 31,
2019 and June 30, 2019 filed on February 7, 2019, May 9, 2019 and August 13, 2019, respectively. These reports and any future filings
made with the SEC under Section 12(b) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), can
be obtained by visiting the Securities and Exchange Commission’s website at http://www.sec.gov. The Subscriber agrees that
it is not relying on any other written information which may have been provided by the Company.

 

j.                          The
Subscriber represents, warrants and agrees that it will not sell or otherwise transfer the Shares without registration under the
Act or an exemption therefrom, and fully understands and agrees that the Subscriber must bear the economic risk of its purchase
because, among other reasons, the Shares have not been registered under the Act or under the securities laws of any state and,
therefore, cannot be resold, pledged, assigned or otherwise disposed of unless they are subsequently registered under the Act and
under the applicable securities laws of such states, or an exemption from such registration is available. In particular, the Subscriber
is aware that the Shares are “restricted securities,” as such term is defined in Rule 144 promulgated under the Act
(“Rule 144”), and they may not be sold pursuant to Rule 144 unless all of the conditions of Rule 144 are met.

 

k.                          The
Company, by and through itself and/or legal counsel, has made no representations or warranties as to the suitability of the Subscriber’s
investment in the Company, the length of time the undersigned will be required to own the Shares, or the profit to be realized,
if any, as a result of investment in the Company. Neither the Company nor its counsel has made an independent investigation on
behalf of the Subscriber, nor has the Company, by and through itself and counsel, acted in any advisory capacity to the Subscriber.

 

l.                          The
Company, by and through itself and/or legal counsel, has made no representations or warranties that the past performance or experience
on the part of the Company, or any partner or affiliate, their partners, salesmen, associates, agents, or employees or of any other
person, will in any way indicate the predicted results of the ownership of the Shares.

 

m.                          The
Company has made available for inspection by the undersigned, and his purchaser representative, if any, the books and records of
the Company. Upon reasonable notice, such books and records will continue to be made available for inspection by investors upon
reasonable notice during normal business hours at the principal place of business of the Company.

 

n.                          The
Shares were not offered to the Subscriber by means of publicly disseminated advertisement or sales literature, nor is the Subscriber
aware of any offers made to other persons by such means.

 

    3

     

    

 

o.                          All
information which the Subscriber has provided to the Company concerning the Subscriber is correct and complete as of the date set
forth at the end of this Subscription Agreement, and if there should be any material adverse change in such information prior to
receiving notification that this subscription has been accepted, the undersigned will immediately provide the Company with such
information.

 

5.                          Agreements
of Subscriber. The Subscriber agrees as follows:

 

a.                          The
sale of the Shares by the Company has not been recommended by any United States federal or other securities commission or regulatory
authority. Furthermore, the foregoing authorities have not confirmed the accuracy or determined the adequacy of this Subscription
Agreement or of any of the Company’s filings with the Securities and Exchange Commission.

 

b.                          The
Shares will not be offered for sale, sold, or transferred other than pursuant to: (i) an effective registration under the Act or
in a transaction otherwise in compliance with the Act; and (ii) evidence satisfactory to the Company of compliance with the applicable
securities laws of other jurisdictions. The Company shall be entitled to rely upon an opinion of counsel satisfactory to it with
respect to compliance with the above laws.

 

c.                          The
Company is under no obligation to register the Shares or to comply with any exemption available for sale of the Shares without
registration, and the information necessary to permit routine sales of securities of the Company under Rule 144 of the Act may
not be available when you desire to resell them pursuant to Rule 144 of the Act. The Company is under no obligation to act in any
manner so as to make Rule 144 available with respect to the Shares.

 

d.                          The
Company may, if it so desires, refuse to permit the transfer of the Shares unless the request for transfer is accompanied by an
opinion of counsel acceptable to the Company to the effect that neither the sale nor the proposed transfer will result in any violation
of the Act or the applicable securities laws of any other jurisdiction.

 

e.                          A
legend indicating that the Shares have not been registered under such securities laws and referring to the restrictions and transferability
of the Shares may be placed on the certificates or instruments delivered to the Subscriber or any substitutes thereof and any transfer
agent of the Company may be instructed to require compliance therewith.

 

6.                          Closing.
The Subscriber understands and agrees that the Company intends to issue the Shares upon receipt by the Company of this Subscription
Agreement, including the Confidential Prospective Purchaser Questionnaire, together with the Subscriber’s funds and certain
other documents to be delivered to the Company by Subscriber. The Subscriber further understands that there may be conditions to
closing this subscription which if not met may result in the return of this subscription hereunder.

 

7.                          Indemnification
of the Company. The undersigned understands the meaning and legal consequences of the representations and warranties contained
herein, and hereby agrees to indemnify and hold harmless, the Company, its respective agents, directors, officers, employees,
attorneys and affiliates from and against any and all damages, losses, costs and expenses (including attorneys’ fees) which
they or any of them may incur by reason of the failure of the Subscriber to fulfill any of the terms of this Subscription Agreement,
or by reason of any breach of the representations and warranties made by the Subscriber herein, or in any document provided by
the Subscriber to the Company.

 

    4

     

    

 

8.                          Representative
Capacity. If an investment in the Company is being made by a corporation, partnership, trust or estate, the undersigned individual
signing on behalf of the Subscriber, represents that he has all right and authority, in his capacity as an officer, managing member,
managing partner, trustee, executor or other representative of such corporation, trust or estate, as the case may be, to make such
decision to invest in the Company and to execute and deliver this Subscription Agreement on behalf of such corporation, partnership,
trust or estate as the case may be, enforceable in accordance with its terms.

 

9.                           Subscription
Not Revocable. The undersigned hereby acknowledges and agrees that the undersigned is not entitled to cancel, terminate or
revoke this Subscription Agreement or any agreements of the undersigned hereunder and that this Subscription Agreement shall survive
the dissolution, death or disability of the undersigned.

 

10.                         Restrictions
on Transferability. The undersigned understands and agrees that the Shares shall not be sold, pledged, hypothecated or otherwise
transferred unless the Shares are registered under the Act and applicable state securities laws or an exemption from such registration
is available.

 

11.                         Governing
Law; Jurisdiction; Jury Trial. This Subscription Agreement is being delivered and is intended to be performed in the State
of New York, and shall be construed and enforced in accordance with the laws of such state which shall govern the rights of parties
without regard to conflict of laws principles. Each party hereby irrevocably submits to the exclusive jurisdiction of the state
and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that he or it is not personally subject to the jurisdiction of any such court, that
such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION
OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTION CONTEMPLATED HEREBY. 

 

12.                         Numbers
and Gender. In this Agreement, the masculine gender includes the feminine gender and the neuter and the singular includes the
plural, where appropriate to the context.

 

THIS SPACE INTENTIONALLY LEFT BLANK

 

    5

     

    

 

CONFIDENTIAL
PROSPECTIVE PURCHASER QUESTIONNAIRE

 

This questionnaire is to be completed by
each accredited investor (“Accredited Investor”) as defined in Rule 501 promulgated under the United States
Securities Act of 1933, as amended (the “Securities Act”) who desires to purchase from Applied DNA Sciences,
Inc., a Delaware corporation (the “Company”), shares of the Company’s common stock, par value $0.001 per
share (“Shares”).

 

INSTRUCTIONS

 

This Questionnaire
is being given to the person who has expressed an interest in purchasing Shares of the Company. The purpose of this Questionnaire
is to determine whether you meet certain standards, because the Shares to be offered by the Company have not been, and will not
be, registered under the Securities Act.

 

If the answer to any
questions is “None” or “Not Applicable,” please so state.

 

Your answers will be
kept confidential at all times, however, you hereby agree that the Company may present this Questionnaire to such parties as it
deems appropriate in order to assure itself that the offer and sale of Shares to you will not result in violations of federal or
state securities laws which are being relied upon by the Company in connection with the offer and sale thereof.

 

INSTRUCTIONS: Please type or clearly
print your answer, and state “none” or “not applicable” when appropriate. Please complete Section A and
each other section you are requested to complete in Question A3. If there is insufficient space for any of your answers, please
attach additional pages. If the Shares are to be owned by more than one individual or by a corporation or partnership, you may
need extra copies of this Questionnaire. You may use photocopies or request extra copies from the Company.

  

SECTION A: SUBSCRIBER INFORMATION

 

	A1.         Name(s)
    of Subscriber(s): 	 

 

			 

 

	A2.         Number
of Shares:  	 	 

  

Subscribed
for:  _____________ Shares at a cash purchase price of $___ per share.

 

    	
	Confidential Prospective Purchaser Questionnaire	Page 1

     

    

 

 A3.          Manner of Ownership of Shares (please check below):  

 

	____       One Individual	 	Please complete Section A, B, C and, if applicable, D, E and F.
	 	 	 
	____       Husband and Wife 

Tenants by the Entirety	 	Please have one spouse complete Sections A, B, C and if applicable, D, E and F. Please have both spouses complete Section C.
	 	 	 
	____       Tenants in Common	 	Please have each individual separately complete Sections A, B, and C and if applicable, D, E and F.
	 	 	 
	____       Joint Tenants with Right of Survivorship Two or More Individuals	 	Please have each individual separately complete Sections A, B, and C and if applicable, D, E and F.  (but not husband and wife)
	 	 	 	 
	____       Corporate Ownership	 	Please complete Sections A, B, D and, if applicable, E and F for the corporation.  Please have each person who owns an equity interest in the  corporation separately  complete Sections B and, if applicable, C, D, E and F.
	 	 	 
	____       Partnership Ownership	 	Please complete Sections A, B and D, and have each general partner and limited partner separately complete Sections B, C, D, E and F, if applicable.
	 	 	 
	____       Trust Ownership	 	Please complete Sections A, B and F, if applicable, and have each beneficiary and trustee of the trust separately complete Sections B, C, D, E and F, if applicable.

 

SECTION B:  ACCREDITED INVESTOR STATUS

 

		B1.	Please check one or more of the following definitions of “accredited investor,” if
any, which applies to you. If none of the following applies to you, please leave a blank.

 

______ (a)            A
Bank as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in
Section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity; any broker or dealer registered
pursuant to Section 15 of the Securities Exchange Act of 1934 (the “Exchange Act”); an insurance company as
defined in Section 2(13) of the Securities Act; an investment company registered under the Investment Company Act of 1940 or a
business development company as defined in Section 2(a)(48) of that act; a Small Business Investment Company licensed by the U.S.
Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and
maintained by a state, or its political subdivisions, or any agency or instrumentality of a state or its political subdivisions
for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning
of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section
3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment advisor, or
if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made
solely by persons that are Accredited Investors.

 

    	
	Confidential Prospective Purchaser Questionnaire	Page 2

     

    

 

______ (b)           A
Private Business Development Company as defined in Section 202(a) (22) of the Investment Advisers Act of 1940.

 

______ (c)           An
organization described in Section 501(c)(3) of the Internal Revenue Code or corporation, Massachusetts or similar business trust,
or partnership, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000.

 

______ (d)           A
natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of purchase exceeds
$1,000,000, excluding the value of the person’s primary residence.

 

______ (e)           A
natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that
person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income
level in the current year.

 

______ (f)           Any
trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose purchase
is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D.

 

______ (g)           Any
entity in which all of the equity owners are Accredited Investors.

 

    	
	Confidential Prospective Purchaser Questionnaire	Page 3

     

    

 

SECTION C: INDIVIDUAL INFORMATION

 

		C1.	General Information:

 

	Name:	 

 

	Age:		   Social Security Number (if applicable):	 

 

	Marital Status: 		   Spouse’s Name:	 

  

If the Securities are to be owned by two
or more individuals (not husband and wife), are you related to any other co-owner(s)?

 

Yes  _____
    No  _____

 

If yes, please explain
the relationship(s):

 

			 

 

			 

 

		C2(a).	Principal Residence:

 

	Address:	 
	 	Number                                                                                                          Street
	 	 
	 	 
	 	City                                                State/Province
    Country                       
                          Zip
    code

 

Mailing Address (if
other than Principal Residence above):

 

		 
	 	Number                                                                                                          Street
	 	 
	 	 
	 	City                                                State/Province
    Country                       
                          Zip
    code

  

Telephone
Number:  (        )                                           -                                         

		C2(b).	Have you ever resided in the United States (including
its territories and possessions) or held a United States passport?

 

Yes  ____     No  _____

 

If yes, please
explain where you lived, how long you lived there, or when you held the passport:

 

    	
	Confidential Prospective Purchaser Questionnaire	Page 4

     

    

 

		C3.	Current Employment or Business Activity:

 

	Company Name:	 

 

	Address:	 
	 	Number                                                                                                          Street
	 	 
	 	 
	 	City                                                State/Province
    Country                       
                          Zip
    code

 

	Principal
Business:	 
	 	 
	Position and Title: 	 

  

Description of Duties
and Responsibilities:

 

			 

 

Length of
Time in Present Position:  _____________________

 

Is the company publicly
owned?:      Yes  _____       No  _____

 

		C4.	Education: Please describe your business and/or professional
education or training, listing any schools you have attended and degrees you have received.

 

	Dates	 	Company Name
 and Address	 	Principal Business	 	Description of Duties
 and Responsibilities
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	 	 	 

 

    	
	Confidential Prospective Purchaser Questionnaire	Page 5

     

    

 

		C5.	Prior Employment or Business Activity: Please describe
your prior employment or principal business activities during the last five years, providing all information requested below.

 

	Dates	 	Company Name

and Address	 	Principal

Business	 	Position &

Title	 	Description of

Duties and 

Responsibilities
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

		C6.	The undersigned will provide a financial statement if
requested by the Company.

 

		C7.	Net worth, inclusive of the net worth of your spouse
and inclusive of the value of your principal residence, furnishings therein and personal automobiles:

 

	(  ) less than $100,000	(  ) $100,000 to $199,999
	 	 
	(  ) $200,000 to $499,999	(  ) $500,000 to $1,000,000
	 	 
	(  ) over $1,000,000	 

  

		C8.	Net worth: Your net worth, inclusive of the net worth
of your spouse and excluding the value of your principal residence, furnishings therein and personal automobiles:

 

	(  ) less than $100,000	(  ) $100,000 to $199,999
	 	 
	(  ) $200,000 to $499,999	(  ) $500,000 to $1,000,000
	 	 
	(  ) over $1,000,000	 

 

    	
	Confidential Prospective Purchaser Questionnaire	Page 6

     

    

 

 

		C9.	Indicate (a) your individual income from all sources
for the calendar years 2018 and 2017 and estimated income for 2019 or (b) your joint income with your spouse from all sources
for the calendar years 2018 and 2017 and estimated income for 2019:

 

(a)       individual
income:

 

	 	 	$60,000
 to
 $100,000	 	$100,001
 to
 $199,999	 	$200,000
 to
 $499,999	 	$500,000
 and
 over
	2017	 	(   )	 	(   )	 	(   )	 	(   )
	2018	 	(   )	 	(   )	 	(   )	 	(   )
	2019 (est.)	 	(   )	 	(   )	 	(   )	 	(   )

 

(b)       joint
income:

 

	 	 	$60,000
 to
 $100,000	 	$100,001
 to
 $199,999	 	$200,000
 to
 $499,999	 	$500,000
 and
 over
	2017	 	(   )	 	(   )	 	(   )	 	(   )
	2018	 	(   )	 	(   )	 	(   )	 	(   )
	2019 (est.)	 	(   )	 	(   )	 	(   )	 	(   )

 

		C10.	(a)       Was some portion of your income during your last
taxable year taxed at the highest rate for income tax purposes?

 

_____  Yes             _____  No

 

			(b)       Do you anticipate
that some portion of your income during your current taxable year will be taxed at the highest rate for income tax purposes?

 

_____  Yes             _____  No

 

    	 	Confidential Prospective Purchaser Questionnaire	Page 7

     

    

 

		C11.	Investment experience:

 

			(a)       The frequency with which you invest in marketable
securities is:

 

(   )  often        (   )  occasionally        (   )  never

 

			(b)       The frequency with which you invest in unmarketable
securities is:

 

(   )  often        (   )  occasionally        (   )  never

 

SECTION D: CORPORATE OFFEREES OR PARTNERSHIP OFFEREES

 

		D1.	General Information

 

	Legal Name of Corporation or Partnership: 	 

 

		 	 

 

	Fictitious name: 	 

 

		 	 

 

	Country of Incorporation:	 

 

	Date of Incorporation:	 

 

	I.D. Number (if applicable): 	 

 

	Fiscal Year Ends:	 

 

	Number of Equity Owners: 	 

 

	Name and Title of Executive Officer Executing
Questionnaire: 	 

 

	D2.         Business Address:	 

 

		 	 

 

	Mailing Address (if
different):	 

 

		 	 

 

	Telephone Number:  	(    )

 

Was the corporation
or partnership formed for the specific purpose of purchasing securities?

 

_____  Yes             _____  No

 

Check if applicable
to the corporation:

 

Subchapter S ______________________                      Professional _______________________

 

    	 	Confidential Prospective Purchaser Questionnaire	Page 8

     

    

 

		D3.	The undersigned represents and warrants as follows:

 

		(a)	The corporation or partnership, as the case may be, has been duly incorporated or formed (if a
partnership), is validly existing as a corporation or partnership in good standing under the laws of the jurisdiction of its incorporation
or formation with full power and authority to enter into the transactions contemplated by the Subscription Agreement;

 

		(b)	(i)        The officers or partners of the undersigned who, on behalf of the undersigned, have considered
the purchase of the Shares and the advisers, if any, of the corporation or the partnership, as the case may be, in connection with
such consideration are named below in this Questionnaire, and such officers and advisors or partners, if any, were duly authorized
to act for the corporation or the partnership in reviewing such investment;
	 	 	 
	 	 	(ii)       The names and positions
of the officers or partners, of the undersigned who, on its behalf, have reviewed the purchase of the Shares are as follows:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	(iii)      In
evaluating the merits and risks of the purchase of the Shares the corporation or the partnership, as the case may be, intends to
rely upon the advice of, or will consult with, the following persons:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
		(c)	The officers of the corporation (if not Accredited Investors) or the partners of the partnership
who, on its behalf, have considered the purchase of the Shares and the advisors, if any, of the corporation or the partnership
who, in connection with such consideration, together have such knowledge and experience in financial and business matters that
such officer(s), partner(s) and such advisor(s), if any, together are capable of evaluating the merits and risks of the purchase
of the Shares and of making an informed investment decision;

 

    	 	Confidential Prospective Purchaser Questionnaire	Page 9

     

    

 

		(d)	Together with any corporation or group of corporations with which it files a consolidated federal
income tax return, the undersigned has reserves and/or net worth adequate to permit it to satisfy any tax or other liabilities
arising from its liability with respect to the investment and the operation thereof;
	 	 	 
		(e)	The net worth of the corporation or the partnership is in excess of $__________________.
	 	 	 

		(f)	The corporation or the partnership has had, during each of the past two fiscal or tax years, gross
income from all sources of at least $__________________ and $_____________________ respectively;
	 	 	 

		(g)	The undersigned expects the corporation or the partnership to have during the current fiscal or
tax year, gross income from all sources of at least $_______________; and
	 	 	 

		(h)	The undersigned knows of no pending or threatened litigation the outcome of which could adversely
affect the answer to any question hereunder;
	 	 	 

		(i)	Indicate the following if a partnership offeree:

 

			(1)	The date the partnership was formed and state of formation:	 

 

			(2)	The
names of each partner in the partnership:
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 

 

    	 	Confidential Prospective Purchaser Questionnaire	Page 10

     

    

 

Please have each individual partner execute
a separate Questionnaire.

 

Section E:              Trust Offerees

 

		E1.	General Information:

 

	Legal Name: 	 

 

	Country
of Formation:	 

 

	Date of Formation:	 

 

	I.D. Number:		Fiscal Year Ends:	 

 

	Number of
Beneficiaries:	 

 

	Principal
Purpose:	 

 

Was the trust
formed for the specific purpose of purchasing Securities?

 

_____  Yes             _____  No

 

Is any trustee
a United States person, as that term is defined in Rule 902(k) promulgated under the Securities Act?

 

_____  Yes             _____  No

 

	E2.         Business Address:	 

 

		 	 

 

	Telephone Number:  	(    )

 

	Mailing Address:	 

 

		 	 

 

		E3.	Authorization: If the trust was established in connection
with a deferred compensation plan, please attach a copy of the trust’s organizational documents and a properly certified
copy of the resolutions adopted by the trust’s board of directors authorizing the trust to purchase the Shares and authorizing
the trustee named below to execute on behalf of the trust all relevant documents necessary to subscribe for and purchase the Shares.
In all cases, please attach a properly certified copy of the resolutions adopted by the trustees of the trust authorizing the
trust to purchase the Shares and authorizing the trustee named below to execute on behalf of the trust all relevant documents
necessary to subscribe for and purchase the Shares.

 

	Name of
Authorized Trustee: 	

 

 

    	 	Confidential Prospective Purchaser Questionnaire	Page 11

     

    

 

Section F:              Qualified Pension Plan (“Plan”)
Offerees

 

		F1.	Please initial the appropriate space below:

 

	________

(initial)	a.	The Plan requires the investment of each beneficiary or participant to be held in a segregated account and the Plan allows each beneficiary or participant to make his own investment decisions and, the decision to purchase the Shares has been made by the beneficiary or the participant and such beneficiary or participant is an Accredited Investor (Please have each such beneficiary or participant execute a separate Questionnaire)
	 	 	 
	 	 	OR
	 	 	 
	________

(initial)	b.	The investment decisions made for the Plan are made by a plan fiduciary, whether a bank, an insurance company, or a registered investment advisor.
	 	 	 
	 	 	OR
	 	 	 
	________

(initial)	c.	The Plan has total assets exceeding $5,000,000.

 

		F2.	General Information:

 

	Legal Name: 	 

 

	Country
of Formation:	 

 

	Date of Formation:	 

 

	I.D. Number:		Fiscal Year Ends:	 

 

	Number of
Beneficiaries:	 

 

	Principal
Purpose:	 

 

 

	F3.         Business
    Address:	 

 

			 

 

	Telephone
Number:	(       ) 

 

	Mailing Address: 	

 

			 

 

    	
	Confidential Prospective Purchaser Questionnaire	Page 12

     

    

 

		F4.	Authorization: If the investment decision is being made
by a beneficiary or participant of a Plan, please attach applicable trust documents which permit each beneficiary or participant
to make his own investment decisions. In all other cases, please attach a properly certified copy of the resolutions adopted by
the trustees of the Plan trust authorizing the Plan to purchase the Shares and authorizing the fiduciary named below to execute
on behalf of the Plan all relevant documents necessary to subscribe for and purchase the Shares.

 

	Name of Authorized
Fiduciary: 	 

 

		F5.	Is any beneficiary or participant of a Plan a United
States person, as that term is defined in Rule 902(k) promulgated under the Securities Act?

 

_____  Yes             _____  No

 

THIS SPACE INTENTIONALLY LEFT BLANK; SIGNATURE
PAGE FOLLOWS

 

    	
	Confidential Prospective Purchaser Questionnaire	Page 13

     

    

 

APPLIED DNA SCIENCES, INC.

SIGNATURE PAGE TO

QUESTIONNAIRE AND SUBSCRIPTION AGREEMENT

 

Your signature on this
Signature Page evidences your agreement to be bound by the Questionnaire and the Subscription Agreement.

 

The undersigned represents
that (a) he/she has read and understands this Subscription Agreement, (b) the information contained in this Questionnaire is complete
and accurate and (c) he/she will contact the Company immediately if any material change in any of this information occurs before
the acceptance of his/her subscription and will promptly sent the Company written confirmation of such change.

 

IN WITNESS
WHEREOF, the undersigned has executed this Questionnaire and Subscription Agreement on the date set forth below.

 

Date of Execution:        _________, 2019

 

FOR INDIVIDUALS:

 

 

	 		
	 	 	(Print Name)
	 	 	 
	Dated: _________, 2019	 	 
	 	 	(Signature)
	 	 	 
	 	 	 
	 	 	FOR CORPORATIONS:
	 	 	 
	 	 	 
	 	 	Name of Company
	 	 	 
	 	 	 
	 	 	 
	 	 	Executive Officer of Company
	 	 	 
	Dated: _________, 2019	 	 
	 	 	Signature of Officer

 

[SIGNATURE PAGE TO QUESTIONNAIRE AND SUBSCRIPTION
AGREEMENT]

 

     

     

    

 

	 	 	FOR PARTNERSHIPS:
	 	 	 
	 	 	 
	 	 	 
	 	 	Name of Partnership
	 	 	 
	 	 	 
	 	 	 
	 	 	Name of Partner executing Questionnaire
	 	 	 
	 	 	 
	Dated: _________, 2019	 	 
	 	 	Signature of Partner executing Questionnaire
	 	 	 
	 	 	 
	 	 	FOR TRUSTS:
	 	 	 
	 	 	 
	 	 	 
	 	 	Name of Trust
	 	 	 
	 	 	 
	 	 	 
	 	 	Name of Authorized Trustee Executing Questionnaire
	 	 	 
	Dated: _________, 2019	 	 
	 	 	Signature of Authorized Trustee
	 	 	 
	 	 	 
	 	 	FOR QUALIFIED PENSION PLANS:
	 	 	 
	 	 	 
	 	 	Name of Qualified Pension Plan
	 	 	 
	 	 	and
	 	 	 
	 	 	 
	 	 	Name of Plan Fiduciary executing Questionnaire

 

[SIGNATURE PAGE TO QUESTIONNAIRE
AND SUBSCRIPTION AGREEMENT]

 

     

     

    

 

	Dated: _________, 2019	 	 
	 	 	Signature of Plan Fiduciary executing Questionnaire
	 	 	 
	 	 	 
	 	 	 
	 	 	or
	 	 	 
	 	 	 
	 	 	Name of Plan Beneficiary executing Questionnaire
	 	 	 
	 	 	or
	 	 	 
	Dated: _________, 2019	 	 
	 	 	Signature of Plan Beneficiary executing Questionnaire
	 	 	 
	 	 	 
	APPROVED THIS [●] DAY OF AUGUST , 2019	 	 
	 	 	 
	APPLIED DNA SCIENCES, INC.	 	 

 

	 	 	 	 
	By:	 	 	 
		Name:	 	 
		Title:	 	 

 

[SIGNATURE PAGE TO QUESTIONNAIRE
AND SUBSCRIPTION AGREEMENT]Exhibit 10.1

 

Memo

 

	Date:	August 20, 2019	 
	To:	 	 
	From:	Adam Pascale, CFO
	Re:	Salary Adjustment and Grant of
    Restricted Stock Award 

 

 

You
are receiving this memo because you are an employee of Hemispherx Biopharma, Inc. (the “Company”) and your annual
salary is in excess of $150,000.

 

As
you are aware, the Board of Directors determined that all employees earning in excess of $150,000 per year are required to forego
25% of their salary. 

 

This
salary reduction takes effect for the payroll period commencing
October 1, 2019 and will remain in effect until discontinued by the Board. The Board believes that this will be a temporary
measure.

 

To
incentivize the effected employees, each effected employee will be granted restricted stock awards (each,
an “Award”) pursuant to the Company’s 2018 Equity Incentive Plan. The Awards will be issued at the end of
each semi-monthly pay period commencing with the pay period ending October 15, 2019. The number of shares of common stock to
be issued pursuant to each Award shall be computed as follows: 25% of one twenty-fourth (1/24) of the employee’s annual
salary divided by the per share closing price of the Company’s Common stock on the NYSE American on the trading day
prior to the end of each semi-monthly pay period. The Awards will vest six months after issuance at which time the effected employees will receive the share of common stock pursuant to the Award. The employee must remain
in the employ of the Company during the vesting period and the Awards are not
transferable until after they have vested. A copy of the Form of Restricted Stock Award is attached hereto.

 

Before
making a decision, please review the Form of Restricted Stock Award as well as the Company’s Annual Report on Form
10-K for the year ended December 31, 2018 and all documents subsequently filed by it with the Securities and Exchange Commission
pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Act of 1933.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]